Anna B Halpern

11PUBLICATIONS
48CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Respiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 13, 2026
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Apr 03, 2025
Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.

Matthew Wu, Kathryn Russell, Carole M Shaw

|Jun 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.

Anna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus

|Dec 12, 2022
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.

Carla S Walti, Anna B Halpern, Hu Xie

|Oct 05, 2021
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.

Anna B Halpern, Megan Othus, Nicholas P Howard

Pageof 2

Frequent Collaborators

9 joint publications

Roland B Walter

4 joint publications

Mary-Elizabeth M Percival

4 joint publications

Jacob S Appelbaum

3 joint publications

Pamela S Becker